MDGL

Madrigal Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website madrigalpharma.com
Employees(FY) 92
ISIN US5588681057

Performance

-6.47%

+47.87%

+23.51%

+44.09%

+37.04%

YTD

+66.85%

Profile

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.

Advanced Technical Analysis

Technical Analysis of MDGL 2024-11-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90, indicating robust upward momentum, while the Technical Score of 70 further supports this positive outlook. However, the Oscillators Score of 50 suggests a neutral stance, indicating potential consolidation or indecision in the short term.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of MDGL

Stock Rank

Recent News & Updates

2024-11-18 02:53
The first MASH drug could open the door for others — including GLP-1s(Pharma Voice)
2024-11-14 21:12
John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC(GuruFocus.com)
2024-11-11 07:47
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance(Zacks)
2024-11-10 09:30
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More(Motley Fool)
2024-11-08 07:18
5 Small Drug Stocks to Buy as Trump Gets Re-Elected(Zacks)
2024-11-07 09:10
3 High Growth Tech Stocks Leading The US Market(Simply Wall St.)
2024-11-06 08:00
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences(GlobeNewswire)
2024-11-06 03:28
Madrigal Pharmaceuticals Insider Sold Shares Worth $1,504,703, According to a Recent SEC Filing(MT Newswires)
2024-11-05 19:00
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences(Globenewswire)
2024-11-05 09:14
B. Riley Adjusts Price Target on Madrigal Pharmaceuticals to $236 From $194, Maintains Neutral Rating(MT Newswires)
2024-11-04 09:55
Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations(GuruFocus.com)
2024-11-02 12:00
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH(TipRanks)
2024-11-02 10:14
Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts(Simply Wall St.)
2024-11-01 16:17
Madrigal Pharmaceuticals stock jumps on MASH drug hopes(Yahoo Finance Video)
2024-11-01 13:21
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH(Investor's Business Daily)
2024-11-01 10:07
UBS Adjusts Price Target on Madrigal Pharmaceuticals to $441 From $411, Maintains Buy Rating(MT Newswires)
2024-11-01 09:42
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up(Zacks)
2024-11-01 03:03
Madrigal Pharmaceuticals Inc (MDGL) Q3 2024 Earnings Call Highlights: Strong Sales and ...(GuruFocus.com)
2024-10-31 15:26
Sector Update: Health Care(MT Newswires)
2024-10-31 09:50
Madrigal Pharmaceuticals' Shares Rise After Reporting Narrower Q3 Loss(MT Newswires)
2024-10-31 07:28
Madrigal: Q3 Earnings Snapshot(Associated Press Finance)
2024-10-31 07:00
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates(GlobeNewswire)
2024-10-30 19:00
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates(Globenewswire)
2024-10-30 08:00
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®(GlobeNewswire)
2024-10-29 20:00
Madrigal Pharmaceuticals to Present Multiple Rezdiffra (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting(Globenewswire)
2024-10-22 06:53
Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug(Clinical Trials Arena)
2024-10-21 08:00
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis(GlobeNewswire)
2024-10-20 20:00
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis(Globenewswire)
2024-10-18 08:00
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024(GlobeNewswire)
2024-10-17 20:00
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024(Globenewswire)

Page 1 of 10

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.